Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

ology, University Hospital, Uppsala. "In past randomized studies using either IL-2 alone or similar agents we have not seen evidence of significant benefit to the patients. The Maxamine results suggest the potential for a meaningful advancement in the care of AML patients."

Patients treated in their second or subsequent remission ("CR2+") historically have a poor prognosis with about 5% achieving long-term survival. The 13 CR2+ patients treated with Maxamine Therapy in the ongoing Phase II study have experienced a substantial increase in remission duration, highlighted by the following results updated as of September 1, 1998:

The median time to relapse for the CR2+ patients was 21 months, more than three times the six-month historic median.

Only 10-20% of AML patients under the current standard of care historically achieve remission inversions, the lengthening of subsequent remission times beyond the duration of their previous remissions. However, 8 of 11 (73%) of the evaluable CR2+ patients treated with Maxamine Therapy have achieved remission inversion.

Moreover, 38% of the CR2+ patients treated with Maxamine Therapy remain in leukemia-free remission.

Quality of Life during Maxamine Therapy

In the Phase II study, patients have administered more than 8,000 doses of Maxamine at home. No unexpected side effects from the drug have been identified during the study. The majority, 75%, of the evaluable patients have returned to work while taking Maxamine Therapy. The study results suggest that the administration of Maxamine Therapy at home as a remission therapy for AML is both safe and feasible.

"Quality of life is very important for AML patients during remission," said Dr. Brune. "The ability to provide remission therapy on an outpatient, at-home, basis is essential to allow the patients to maintain as closely as possible their normal lifestyle."

Maxamine Mechanism of Action

In many patients with chronic infectious

Contact: Amy Flood
415-677-4455 x211
Noonan/Russo Communications

Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:

(Date:11/15/2018)... ... , ... The National Cancer Institute estimates that 1.7 million new cases of ... for cancer and we typically associate the disease with old age, about 9 percent ... treatment and advanced therapies, increasing numbers of these patients survive their disease and face ...
(Date:11/15/2018)... ... November 15, 2018 , ... Lisa Vuich MD ... for Specialty MED Training will take the stage during the 26th World ... 2019. Dr. Vuich is leading a CME workshop hosted by Tailor Made Compounding ...
(Date:11/14/2018)... ... November 14, 2018 , ... Entrepreneur ... All-In-One Video Ecommerce Solution, to power its "Ask an Expert" online mentor marketplace. ... live 30 and 60-minute one-to-one virtual sessions that are focused on starting and ...
(Date:11/14/2018)... ... 14, 2018 , ... The Austin-area sports medicine team at Medicine ... pull out the healthcare plan paperwork to review coverage and assess how many unused ... most people can benefit by taking a few minutes for an insurance plan evaluation. ...
(Date:11/13/2018)... ... November 13, 2018 , ... Azzur Labs, ... the opening of its newest laboratory located in Cary, NC. Seated in the ... services to top U.S. manufacturers and brings additional jobs to the Raleigh area. ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... Del. (PRWEB) , ... November 15, 2018 , ... ... over 61% in 2016 and is estimated to continue its dominance during the ... industrial segment. Mobile exoskeleton provides mobility to the wearer while augmenting strength to ...
(Date:11/15/2018)... Calif. (PRWEB) , ... November 15, 2018 , ... ... instruments, today announced its participation in the California Optometric Association’s Monterey Fall Symposium. ... The show provides a platform for connecting with hundreds of doctors of optometry. ...
(Date:11/14/2018)... ... November 14, 2018 , ... Planet DDS (PDDS), ... Hannah Cohen was joining the company as its new Vice President of Operations. ... DaVita, one of the nation’s leading managed care providers. At DaVita, Hannah oversaw ...
Breaking Medicine Technology:
Cached News: